Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/54906
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Clinical resistance to imatinib: mechanisms and implications |
Author: | Hochhaus, A. Hughes, T. |
Citation: | Hematology / Oncology Clinics of North America, 2004; 18(3):641-657 |
Publisher: | W B Saunders Co |
Issue Date: | 2004 |
ISSN: | 0889-8588 1558-1977 |
Statement of Responsibility: | Andreas Hochhaus and Timothy Hughes |
Abstract: | Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in most cases, most patients in advanced disease develop resistance and relapse after a short duration of therapy. The mechanisms of drug resistance are diverse, but in most cases, mutations are found at the time of resistance that change amino acids within the kinase domain of BCR-ABL. Cytogenetic and molecular analyses at the time of resistance are suggested to guide therapy. |
Keywords: | Humans Benzamides Piperazines Pyrimidines Fusion Proteins, bcr-abl Drug Resistance, Neoplasm Mutation Leukemia, Myelogenous, Chronic, BCR-ABL Positive Imatinib Mesylate |
DOI: | 10.1016/j.hoc.2004.03.001 |
Published version: | http://dx.doi.org/10.1016/j.hoc.2004.03.001 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.